{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:26:24Z","timestamp":1792765584597,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40257-018-0384-3","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T01:00:49Z","timestamp":1540861249000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":325,"title":["Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails"],"prefix":"10.1007","volume":"19","author":[{"given":"Mario","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"issue":"4","key":"384_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","volume":"14","author":"AC Rosen","year":"2013","unstructured":"Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327\u201333.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"384_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000277656","volume":"33","author":"JC Hassel","year":"2010","unstructured":"Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010;33(3):94\u20138.","journal-title":"Onkologie."},{"issue":"10","key":"384_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803\u201312.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"384_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-012-2157-7","volume":"135","author":"AM Drucker","year":"2012","unstructured":"Drucker AM, Wu S, Dang CT, Lacouture ME. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):347\u201354.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"384_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"384_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1210\/jc.2011-2677","volume":"97","author":"AC Rosen","year":"2012","unstructured":"Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(4):1125\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"384_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","journal-title":"N Engl J Med"},{"issue":"199","key":"384_CR8","doi-asserted-by":"publisher","first-page":"199ra111","DOI":"10.1126\/scitranslmed.3005886","volume":"5","author":"B. M. Lichtenberger","year":"2013","unstructured":"Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5(199):199ra11.","journal-title":"Science Translational Medicine"},{"issue":"17","key":"384_CR9","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-10-0421","volume":"16","author":"B Nardone","year":"2010","unstructured":"Nardone B, Nicholson K, Newman M, Guitart J, Gerami P, Talarico N, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1\/2 inhibitors in cancer patients. Clin Cancer Res. 2010;16(17):4452\u201360.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"384_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"384_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jnci\/djp439","volume":"102","author":"RE Eilers Jr","year":"2010","unstructured":"Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102(1):47\u201353.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"384_CR12","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdw227","volume":"27","author":"ME Lacouture","year":"2016","unstructured":"Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol. 2016;27(9):1712\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"384_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jaad.2017.03.039","volume":"77","author":"VR Belum","year":"2017","unstructured":"Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME. A prospective, randomized, double-blinded, split-face\/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. J Am Acad Dermatol. 2017;77(3):577\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"384_CR14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694\u2013703.","journal-title":"N Engl J Med"},{"issue":"20","key":"384_CR15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376.","journal-title":"N Engl J Med"},{"issue":"26","key":"384_CR16","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"7287","key":"384_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431\u20135.","journal-title":"Nature"},{"issue":"3","key":"384_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2011.38.2895","volume":"30","author":"ME Lacouture","year":"2012","unstructured":"Lacouture ME, O\u2019Reilly K, Rosen N, Solit DB. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol. 2012;30(3):329\u201330.","journal-title":"J Clin Oncol"},{"issue":"3","key":"384_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314\u201322.","journal-title":"Oncologist."},{"issue":"1","key":"384_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/cncr.28980","volume":"121","author":"VR Belum","year":"2015","unstructured":"Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, et al. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer. 2015;121(1):60\u20138.","journal-title":"Cancer"},{"issue":"3","key":"384_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"384_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/jid.2013.462","volume":"134","author":"M Perier-Muzet","year":"2014","unstructured":"Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier PP, Duru G, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134(5):1351\u20138.","journal-title":"J Invest Dermatol."},{"issue":"10","key":"384_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamadermatol.2016.2426","volume":"152","author":"M Perier-Muzet","year":"2016","unstructured":"Perier-Muzet M, Boespflug A, Poulalhon N, Caramel J, Breton AL, Thomas L, et al. Dermoscopic evaluation of melanocytic nevi changes with combined mitogen-activated protein kinase pathway inhibitors therapy for melanoma. JAMA Dermatol. 2016;152(10):1162\u20134.","journal-title":"JAMA Dermatol."},{"key":"384_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.humpath.2015.12.003","volume":"50","author":"K Mudaliar","year":"2016","unstructured":"Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, et al. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016;50:79\u201389.","journal-title":"Hum Pathol"},{"issue":"9992","key":"384_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351.","journal-title":"Lancet"},{"issue":"9","key":"384_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360.","journal-title":"Lancet Oncol."},{"issue":"9","key":"384_CR27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1056\/NEJMc1114329","volume":"366","author":"JJ Harding","year":"2012","unstructured":"Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 2012;366(9):866\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"384_CR28","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1111\/jdv.13892","volume":"31","author":"K Imafuku","year":"2017","unstructured":"Imafuku K, Yoshino K, Ymaguchi K, Tsuboi S, Ohara K, Hata H. Nivolumab therapy before vemurafenib administration induces a severe skin rash. J Eur Acad Dermatol Venereol. 2017;31(3):e169\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"384_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00105-015-3590-4","volume":"66","author":"N Klossowski","year":"2015","unstructured":"Klossowski N, Kislat A, Homey B, Gerber PA, Meller S. Successful drug desensitization after vemurafenib-induced rash [in German]. Hautarzt. 2015;66(4):221\u20133.","journal-title":"Hautarzt."},{"issue":"19","key":"384_CR30","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"384_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559\u201374.","journal-title":"Ann Oncol"},{"issue":"4","key":"384_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254\u201363.","journal-title":"Curr Opin Oncol"},{"key":"384_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12\u201325.","journal-title":"Eur J Cancer"},{"issue":"10","key":"384_CR34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","volume":"41","author":"GJ Kaunitz","year":"2017","unstructured":"Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, et al. Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern. Am J Surg Pathol. 2017;41(10):1381\u20139.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"384_CR35","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10):1128\u201336.","journal-title":"JAMA Dermatol."},{"issue":"4","key":"384_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/cup.12666","volume":"43","author":"KB Schaberg","year":"2016","unstructured":"Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339\u201346.","journal-title":"J Cutan Pathol"},{"issue":"5","key":"384_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","volume":"69","author":"CJ Ensslin","year":"2013","unstructured":"Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"384_CR38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","volume":"4","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"384_CR39","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/jdv.14011","volume":"31","author":"J Bonigen","year":"2017","unstructured":"Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31(5):e254\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"384_CR40","first-page":"560","volume":"4","author":"J Villadolid","year":"2015","unstructured":"Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560\u201375.","journal-title":"Transl Lung Cancer Res."},{"issue":"1","key":"384_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45\u201351.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"384_CR42","doi-asserted-by":"publisher","first-page":"902-910.e2","DOI":"10.1016\/j.jaad.2017.06.044","volume":"77","author":"Julia Dai","year":"2017","unstructured":"Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(5):902\u201310.e2.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"384_CR43","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","volume":"1","author":"JA Lo","year":"2015","unstructured":"Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015;1(9):1340\u20131.","journal-title":"JAMA Oncol."},{"issue":"11","key":"384_CR44","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206\u201312.","journal-title":"JAMA Dermatol."},{"issue":"4","key":"384_CR45","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886\u201394.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"384_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/annonc\/mdv595","volume":"27","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016;27(3):519\u201325.","journal-title":"Ann Oncol"},{"issue":"5","key":"384_CR47","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","volume":"25","author":"E Vigarios","year":"2017","unstructured":"Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25(5):1713\u201339.","journal-title":"Support Care Cancer"},{"issue":"Suppl 5","key":"384_CR48","doi-asserted-by":"publisher","first-page":"v139","DOI":"10.1093\/annonc\/mdv202","volume":"26","author":"DE Peterson","year":"2015","unstructured":"Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015;26(Suppl 5):v139\u201351.","journal-title":"Ann Oncol"},{"issue":"5","key":"384_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654\u201362.","journal-title":"Lancet Oncol."},{"issue":"4","key":"384_CR50","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1634\/theoncologist.2012-0320","volume":"18","author":"T Hubiche","year":"2013","unstructured":"Hubiche T, Valenza B, Chevreau C, Fricain JC, Del Giudice P, Sibaud V. Geographic tongue induced by angiogenesis inhibitors. Oncologist. 2013;18(4):e16\u20137.","journal-title":"Oncologist."},{"issue":"6","key":"384_CR51","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/bjd.13610","volume":"172","author":"E Vigarios","year":"2015","unstructured":"Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barres B, et al. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors. Br J Dermatol. 2015;172(6):1680\u20132.","journal-title":"Br J Dermatol"},{"issue":"10","key":"384_CR52","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","volume":"151","author":"G Carlos","year":"2015","unstructured":"Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103\u20139.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"384_CR53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.annder.2014.03.009","volume":"141","author":"V Sibaud","year":"2014","unstructured":"Sibaud V, Boralevi F, Vigarios E, Fricain JC. Oral toxicity of targeted anticancer therapies [in French]. Ann Dermatol Venereol. 2014;141(5):354\u201363.","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"384_CR54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.lpm.2017.02.005","volume":"46","author":"JC Fricain","year":"2017","unstructured":"Fricain JC, Sibaud V. Pigmentations of the oral cavity [in French]. Presse Med. 2017;46(3):303\u201319.","journal-title":"Presse Med"},{"issue":"10","key":"384_CR55","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1111\/jdv.14284","volume":"31","author":"V Sibaud","year":"2017","unstructured":"Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, et al. Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol. 2017;31(10):e464\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"384_CR56","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","volume":"26","author":"VR Belum","year":"2015","unstructured":"Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol. 2015;26(12):2496\u2013502.","journal-title":"Ann Oncol"},{"issue":"4","key":"384_CR57","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jaad.2015.01.011","volume":"72","author":"BM Piraccini","year":"2015","unstructured":"Piraccini BM, Patrizi A, Fanti PA, Starace M, Bruni F, Melotti B, et al. RASopathic alopecia: hair changes associated with vemurafenib therapy. J Am Acad Dermatol. 2015;72(4):738\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"384_CR58","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/jid.2013.368","volume":"134","author":"X Wang","year":"2014","unstructured":"Wang X, Marr AK, Breitkopf T, Leung G, Hao J, Wang E, et al. Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege. J Invest Dermatol. 2014;134(3):736\u201345.","journal-title":"J Invest Dermatol."},{"issue":"6","key":"384_CR59","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjd.15237","volume":"176","author":"A Zarbo","year":"2017","unstructured":"Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176(6):1649\u201352.","journal-title":"Br J Dermatol"},{"issue":"10","key":"384_CR60","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Wu S, Dickler MN, Lacouture ME. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013;18(10):1126\u201334.","journal-title":"Oncologist."},{"issue":"6","key":"384_CR61","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670\u20135.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"384_CR62","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/j.1365-2133.2012.11180.x","volume":"167","author":"J Lindner","year":"2012","unstructured":"Lindner J, Hillmann K, Blume-Peytavi U, Lademann J, Lux A, Stroux A, et al. Hair shaft abnormalities after chemotherapy and tamoxifen therapy in patients with breast cancer evaluated by optical coherence tomography. Br J Dermatol. 2012;167(6):1272\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"384_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","volume":"67","author":"BC Garden","year":"2012","unstructured":"Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2012;67(3):400\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"384_CR64","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","volume":"16","author":"C Robert","year":"2015","unstructured":"Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181\u20139.","journal-title":"Lancet Oncol."},{"issue":"5","key":"384_CR65","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1365-2133.2010.09906.x","volume":"163","author":"BM Piraccini","year":"2010","unstructured":"Piraccini BM, Bellavista S, Misciali C, Tosti A, de Berker D, Richert B. Periungual and subungual pyogenic granuloma. Br J Dermatol. 2010;163(5):941\u201353.","journal-title":"Br J Dermatol"},{"issue":"3","key":"384_CR66","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaad.2013.02.025","volume":"69","author":"Y Kiyohara","year":"2013","unstructured":"Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69(3):463\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"384_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/jamadermatol.2017.4120","volume":"154","author":"X Cubiro","year":"2018","unstructured":"Cubiro X, Planas-Ciudad S, Garcia-Muret MP, Puig L. Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol. 2018;154(1):99\u2013100.","journal-title":"JAMA Dermatol."},{"issue":"3","key":"384_CR68","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","volume":"161","author":"A Osio","year":"2009","unstructured":"Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3):515\u201321.","journal-title":"Br J Dermatol"},{"issue":"7","key":"384_CR69","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1001\/jamadermatol.2017.0500","volume":"153","author":"S Betrian","year":"2017","unstructured":"Betrian S, Gomez-Roca C, Vigarios E, Delord JP, Sibaud V. Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors. JAMA Dermatol. 2017;153(7):723\u20135.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"384_CR70","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamadermatol.2016.0225","volume":"152","author":"C Bitar","year":"2016","unstructured":"Bitar C, Farooqui MZ, Valdez J, Saba NS, Soto S, Bray A, et al. Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152(6):698\u2013701.","journal-title":"JAMA Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-018-0384-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0384-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0384-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T08:06:50Z","timestamp":1605341210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-018-0384-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":70,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0384-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"30 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Medical writing assistance was funded by Laboratoires dermatologiques Av\u00e8ne. Mario Lacouture and Vincent Sibaud received funds from Laboratoires dermatologiques Av\u00e8ne for traveling to and presenting at the Entretiens d'Av\u00e8ne Americas conference. MEL is funded in part through the NIH\/NCI Cancer Center Support Grant P30 CA008748.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Vincent Sibaud declares he received fees from Laboratoires dermatologiques Av\u00e8ne, Roche, Novartis, Bayer, Pierre Fabre and BMS. Mario Lacouture declares he has received consulting\/advisory fees from Merck Sharp & Dohme Corporation, Galderma, Janssen Research & Development, LLC, Abbvie, Inc., Helsinn Healthcare SA, Novocure Inc., Boehringer Ingelheim Pharma GMBH & Co.KG, F. Hoffmann-La Roche AG, Allergan Inc., Amgen Inc., E.R. Squibb & Sons, L.L.C., Novartis Pharmaceuticals Corporation, EMD Serono, Inc., Astrazeneca Pharmaceuticals LP, Genentech, Inc, Leo Pharma Inc, Seattle Genetics, Debiopharm, Lindi, Bayer, Manner SAS, Menlo Ther, Celldex, Lutris, Pierre Fabre, Legacy Healthcare, Roche, Amryt Pharma, Johnson & Johnson, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Parexel, Adgero, Veloce, Berg, US Biotest and research funding from Veloce, Berg, US Biotest, BMS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is published as part of a journal supplement wholly funded by Laboratoires dermatologiques Av\u00e8ne.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}}]}}